Amylyx (AMLX) announced that the first participant has been dosed in LUMINA, the company’s Phase 1, multinational, randomized, double-blind, placebo-controlled, multiple ascending dose clinical trial of AMX0114, an investigational, potent antisense oligonucleotide targeting calpain-2, in people living with amyotrophic lateral sclerosis. The company continues to expect early cohort data from LUMINA in 2025.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AMLX:
- Amylyx upgraded to Outperform from Neutral at Mizuho
- Cautious Hold Rating for Amylyx Pharmaceuticals Amid Key Clinical Updates and Stable Financial Position
- Buy Rating for Amylyx Pharmaceuticals: Avexitide’s Potential in Post-Bariatric Surgery Market
- Amylyx Pharmaceuticals Faces Challenges in Acquisition Strategy Amid RELYVRIO Discontinuation
- Amylyx Pharmaceuticals Reports 2024 Financial Results